CAR-T patients monitored for years in new safety study
NCT ID NCT07474051
First seen Mar 22, 2026 · Last updated May 21, 2026 · Updated 8 times
Summary
This study follows people who previously received an experimental CAR-T cell therapy from AvenCell for cancers like lymphoma, leukemia, or prostate cancer. The goal is to track long-term side effects, including new cancers, nerve problems, or immune disorders. About 178 participants will be monitored over time to better understand the therapy's lasting safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charité Universitätsmedizin Berlin
Berlin, Germany
-
Klinikum der Universität (LMU) Muenchen
Munich, Germany
-
Technische Universitaet Dresden - Universitaetsklinikum Carl Gustav Carus
Dresden, Germany
-
Universitatsklinikum Ulm
Ulm, Germany
-
Universitätsklinikum Marburg
Marburg, Germany
Conditions
Explore the condition pages connected to this study.